Review



cobicistat  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress cobicistat
    Pharmacological inhibition of CYP3A5 suppresses GBM growth and sensitizes GBM to TMZ. (A) Structure of <t>Cobicistat</t> (Cobi). (B) NAD-to-NADH ratios of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (C) Oxygen consumption rate (OCR) alterations of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (D) Cell viability assay with the increasing concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (E) Immunoblots of cleaved PARP, γH2AX, CD133, and PUMA in GSCs treated with Cobi and TMZ. (F) Calculation and visualization of synergy scores for drug combinations of Cobi and TMZ. (G) Representative images and quantification of cell apoptosis measured by flow cytometry ( n = 3). p -values obtained by one-way ANOVA. (H-I) Representative images and quantification of bioluminescence intensities of nude mice intracranially implanted with U87MG GSCs in treatment of DMSO, TMZ(5 mg/kg), Cobi(10 mg/kg) or TMZ(5 mg/kg) + Cobi(10 mg/kg) by gavage ( n = 5). p -values obtained by one-way ANOVA. (J) Kaplan-Meier survival curves of the nude mice ( n = 5). p -values obtained by Log-rank test. (K) Representative images of H&E staining of tumor sections. Scale bars, 2 mm. (L) Representative images and quantification of immunofluorescence staining of Ki-67 ( n = 5). p -values obtained by one-way ANOVA. Scale bars, 50 μm. (M) AST and ALT activity in serum of mice with indicated treatment. (N) Liquid chromatography-tandem mass spectrometry (LC-MS) analysis of Cobi (10 mg/kg, by gavage) concentration in blood plasma, brain, and xenografts from tumor-bearing mice at indicated time points ( n = 3 mice per group). AUC, the area under the curve. Cmax, maximum concentration. Error bars represent mean ± SD. Significant results are presented as, ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Cobicistat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 12 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cobicistat/product/MedChemExpress
    Average 94 stars, based on 12 article reviews
    cobicistat - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "CYP3A5 promotes glioblastoma stemness and chemoresistance through fine-tuning NAD + /NADH ratio"

    Article Title: CYP3A5 promotes glioblastoma stemness and chemoresistance through fine-tuning NAD + /NADH ratio

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    doi: 10.1186/s13046-024-03254-x

    Pharmacological inhibition of CYP3A5 suppresses GBM growth and sensitizes GBM to TMZ. (A) Structure of Cobicistat (Cobi). (B) NAD-to-NADH ratios of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (C) Oxygen consumption rate (OCR) alterations of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (D) Cell viability assay with the increasing concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (E) Immunoblots of cleaved PARP, γH2AX, CD133, and PUMA in GSCs treated with Cobi and TMZ. (F) Calculation and visualization of synergy scores for drug combinations of Cobi and TMZ. (G) Representative images and quantification of cell apoptosis measured by flow cytometry ( n = 3). p -values obtained by one-way ANOVA. (H-I) Representative images and quantification of bioluminescence intensities of nude mice intracranially implanted with U87MG GSCs in treatment of DMSO, TMZ(5 mg/kg), Cobi(10 mg/kg) or TMZ(5 mg/kg) + Cobi(10 mg/kg) by gavage ( n = 5). p -values obtained by one-way ANOVA. (J) Kaplan-Meier survival curves of the nude mice ( n = 5). p -values obtained by Log-rank test. (K) Representative images of H&E staining of tumor sections. Scale bars, 2 mm. (L) Representative images and quantification of immunofluorescence staining of Ki-67 ( n = 5). p -values obtained by one-way ANOVA. Scale bars, 50 μm. (M) AST and ALT activity in serum of mice with indicated treatment. (N) Liquid chromatography-tandem mass spectrometry (LC-MS) analysis of Cobi (10 mg/kg, by gavage) concentration in blood plasma, brain, and xenografts from tumor-bearing mice at indicated time points ( n = 3 mice per group). AUC, the area under the curve. Cmax, maximum concentration. Error bars represent mean ± SD. Significant results are presented as, ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Figure Legend Snippet: Pharmacological inhibition of CYP3A5 suppresses GBM growth and sensitizes GBM to TMZ. (A) Structure of Cobicistat (Cobi). (B) NAD-to-NADH ratios of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (C) Oxygen consumption rate (OCR) alterations of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (D) Cell viability assay with the increasing concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (E) Immunoblots of cleaved PARP, γH2AX, CD133, and PUMA in GSCs treated with Cobi and TMZ. (F) Calculation and visualization of synergy scores for drug combinations of Cobi and TMZ. (G) Representative images and quantification of cell apoptosis measured by flow cytometry ( n = 3). p -values obtained by one-way ANOVA. (H-I) Representative images and quantification of bioluminescence intensities of nude mice intracranially implanted with U87MG GSCs in treatment of DMSO, TMZ(5 mg/kg), Cobi(10 mg/kg) or TMZ(5 mg/kg) + Cobi(10 mg/kg) by gavage ( n = 5). p -values obtained by one-way ANOVA. (J) Kaplan-Meier survival curves of the nude mice ( n = 5). p -values obtained by Log-rank test. (K) Representative images of H&E staining of tumor sections. Scale bars, 2 mm. (L) Representative images and quantification of immunofluorescence staining of Ki-67 ( n = 5). p -values obtained by one-way ANOVA. Scale bars, 50 μm. (M) AST and ALT activity in serum of mice with indicated treatment. (N) Liquid chromatography-tandem mass spectrometry (LC-MS) analysis of Cobi (10 mg/kg, by gavage) concentration in blood plasma, brain, and xenografts from tumor-bearing mice at indicated time points ( n = 3 mice per group). AUC, the area under the curve. Cmax, maximum concentration. Error bars represent mean ± SD. Significant results are presented as, ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Techniques Used: Inhibition, Viability Assay, Western Blot, Flow Cytometry, Staining, Immunofluorescence, Activity Assay, Liquid Chromatography, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy, Concentration Assay



    Similar Products

    cobicistat  (MedChemExpress)
    94
    MedChemExpress cobicistat
    Pharmacological inhibition of CYP3A5 suppresses GBM growth and sensitizes GBM to TMZ. (A) Structure of <t>Cobicistat</t> (Cobi). (B) NAD-to-NADH ratios of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (C) Oxygen consumption rate (OCR) alterations of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (D) Cell viability assay with the increasing concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (E) Immunoblots of cleaved PARP, γH2AX, CD133, and PUMA in GSCs treated with Cobi and TMZ. (F) Calculation and visualization of synergy scores for drug combinations of Cobi and TMZ. (G) Representative images and quantification of cell apoptosis measured by flow cytometry ( n = 3). p -values obtained by one-way ANOVA. (H-I) Representative images and quantification of bioluminescence intensities of nude mice intracranially implanted with U87MG GSCs in treatment of DMSO, TMZ(5 mg/kg), Cobi(10 mg/kg) or TMZ(5 mg/kg) + Cobi(10 mg/kg) by gavage ( n = 5). p -values obtained by one-way ANOVA. (J) Kaplan-Meier survival curves of the nude mice ( n = 5). p -values obtained by Log-rank test. (K) Representative images of H&E staining of tumor sections. Scale bars, 2 mm. (L) Representative images and quantification of immunofluorescence staining of Ki-67 ( n = 5). p -values obtained by one-way ANOVA. Scale bars, 50 μm. (M) AST and ALT activity in serum of mice with indicated treatment. (N) Liquid chromatography-tandem mass spectrometry (LC-MS) analysis of Cobi (10 mg/kg, by gavage) concentration in blood plasma, brain, and xenografts from tumor-bearing mice at indicated time points ( n = 3 mice per group). AUC, the area under the curve. Cmax, maximum concentration. Error bars represent mean ± SD. Significant results are presented as, ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Cobicistat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cobicistat/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    cobicistat - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    compound  (MedChemExpress)
    94
    MedChemExpress compound
    Pharmacological inhibition of CYP3A5 suppresses GBM growth and sensitizes GBM to TMZ. (A) Structure of <t>Cobicistat</t> (Cobi). (B) NAD-to-NADH ratios of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (C) Oxygen consumption rate (OCR) alterations of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (D) Cell viability assay with the increasing concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (E) Immunoblots of cleaved PARP, γH2AX, CD133, and PUMA in GSCs treated with Cobi and TMZ. (F) Calculation and visualization of synergy scores for drug combinations of Cobi and TMZ. (G) Representative images and quantification of cell apoptosis measured by flow cytometry ( n = 3). p -values obtained by one-way ANOVA. (H-I) Representative images and quantification of bioluminescence intensities of nude mice intracranially implanted with U87MG GSCs in treatment of DMSO, TMZ(5 mg/kg), Cobi(10 mg/kg) or TMZ(5 mg/kg) + Cobi(10 mg/kg) by gavage ( n = 5). p -values obtained by one-way ANOVA. (J) Kaplan-Meier survival curves of the nude mice ( n = 5). p -values obtained by Log-rank test. (K) Representative images of H&E staining of tumor sections. Scale bars, 2 mm. (L) Representative images and quantification of immunofluorescence staining of Ki-67 ( n = 5). p -values obtained by one-way ANOVA. Scale bars, 50 μm. (M) AST and ALT activity in serum of mice with indicated treatment. (N) Liquid chromatography-tandem mass spectrometry (LC-MS) analysis of Cobi (10 mg/kg, by gavage) concentration in blood plasma, brain, and xenografts from tumor-bearing mice at indicated time points ( n = 3 mice per group). AUC, the area under the curve. Cmax, maximum concentration. Error bars represent mean ± SD. Significant results are presented as, ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
    Compound, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/compound/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    compound - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Pharmacological inhibition of CYP3A5 suppresses GBM growth and sensitizes GBM to TMZ. (A) Structure of Cobicistat (Cobi). (B) NAD-to-NADH ratios of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (C) Oxygen consumption rate (OCR) alterations of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (D) Cell viability assay with the increasing concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (E) Immunoblots of cleaved PARP, γH2AX, CD133, and PUMA in GSCs treated with Cobi and TMZ. (F) Calculation and visualization of synergy scores for drug combinations of Cobi and TMZ. (G) Representative images and quantification of cell apoptosis measured by flow cytometry ( n = 3). p -values obtained by one-way ANOVA. (H-I) Representative images and quantification of bioluminescence intensities of nude mice intracranially implanted with U87MG GSCs in treatment of DMSO, TMZ(5 mg/kg), Cobi(10 mg/kg) or TMZ(5 mg/kg) + Cobi(10 mg/kg) by gavage ( n = 5). p -values obtained by one-way ANOVA. (J) Kaplan-Meier survival curves of the nude mice ( n = 5). p -values obtained by Log-rank test. (K) Representative images of H&E staining of tumor sections. Scale bars, 2 mm. (L) Representative images and quantification of immunofluorescence staining of Ki-67 ( n = 5). p -values obtained by one-way ANOVA. Scale bars, 50 μm. (M) AST and ALT activity in serum of mice with indicated treatment. (N) Liquid chromatography-tandem mass spectrometry (LC-MS) analysis of Cobi (10 mg/kg, by gavage) concentration in blood plasma, brain, and xenografts from tumor-bearing mice at indicated time points ( n = 3 mice per group). AUC, the area under the curve. Cmax, maximum concentration. Error bars represent mean ± SD. Significant results are presented as, ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: CYP3A5 promotes glioblastoma stemness and chemoresistance through fine-tuning NAD + /NADH ratio

    doi: 10.1186/s13046-024-03254-x

    Figure Lengend Snippet: Pharmacological inhibition of CYP3A5 suppresses GBM growth and sensitizes GBM to TMZ. (A) Structure of Cobicistat (Cobi). (B) NAD-to-NADH ratios of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (C) Oxygen consumption rate (OCR) alterations of GSCs treated with indicated concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (D) Cell viability assay with the increasing concentrations of Cobi ( n = 3). p -values obtained by one-way ANOVA. (E) Immunoblots of cleaved PARP, γH2AX, CD133, and PUMA in GSCs treated with Cobi and TMZ. (F) Calculation and visualization of synergy scores for drug combinations of Cobi and TMZ. (G) Representative images and quantification of cell apoptosis measured by flow cytometry ( n = 3). p -values obtained by one-way ANOVA. (H-I) Representative images and quantification of bioluminescence intensities of nude mice intracranially implanted with U87MG GSCs in treatment of DMSO, TMZ(5 mg/kg), Cobi(10 mg/kg) or TMZ(5 mg/kg) + Cobi(10 mg/kg) by gavage ( n = 5). p -values obtained by one-way ANOVA. (J) Kaplan-Meier survival curves of the nude mice ( n = 5). p -values obtained by Log-rank test. (K) Representative images of H&E staining of tumor sections. Scale bars, 2 mm. (L) Representative images and quantification of immunofluorescence staining of Ki-67 ( n = 5). p -values obtained by one-way ANOVA. Scale bars, 50 μm. (M) AST and ALT activity in serum of mice with indicated treatment. (N) Liquid chromatography-tandem mass spectrometry (LC-MS) analysis of Cobi (10 mg/kg, by gavage) concentration in blood plasma, brain, and xenografts from tumor-bearing mice at indicated time points ( n = 3 mice per group). AUC, the area under the curve. Cmax, maximum concentration. Error bars represent mean ± SD. Significant results are presented as, ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001

    Article Snippet: For combination treatment, 5 mg/kg TMZ (Sigma) and 10 mg/kg cobicistat (MCE) were administered via oral gavage at the indicated frequency.

    Techniques: Inhibition, Viability Assay, Western Blot, Flow Cytometry, Staining, Immunofluorescence, Activity Assay, Liquid Chromatography, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy, Concentration Assay